Therapy Detail

Therapy Name RRx-001
Therapy Description

RRx-001 is a nitric oxide donor that is activated by hypoxia, leading to increased oxygen level in tumor and sensitizes tumor to radiotherapy (PMID: 26164533).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
RRx-001 RRx-001 is a nitric oxide donor that is activated by hypoxia, leading to increased oxygen level in tumor and sensitizes tumor to radiotherapy (PMID: 26164533).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable RRx-001 Phase I Actionable In a Phase I trial, RRx-001 demonstrated safety and preliminary efficacy, resulted in partial response in 5% (1/21) and stable disease in 67% (14/21) of patients with advanced solid tumors (PMID: 26296952; NCT01359982). 26296952
Clinical Trial Phase Therapies Title Recruitment Status
NCT03515538 Phase II Cisplatin + RRx-001 RRx-001 Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers Recruiting
NCT02452970 Phase II RRx-001 Gemcitabine + Cisplatin RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) Active, not recruiting
NCT02215512 Phase I RRx-001 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases Active, not recruiting
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Recruiting